A phase Ib study of a single priming dose of 177Lu-PSMA617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC)

被引：0

作者：

Aggarwal, R. ^{[1
]}

Trihy, L. ^{[2
]}

Hernandez Romero, E. ^{[2
]}

Sam, S. Luch ^{[1
]}

Rastogi, M. ^{[1
]}

De Kouchkovsky, I. ^{[3
]}

Small, E. J. ^{[4
]}

Feng, F. ^{[5
]}

Kwon, D. ^{[3
]}

Friedlander, T. ^{[3
]}

Borno, H. T. ^{[3
]}

Bose, R. ^{[6
]}

Chou, J. ^{[3
]}

Koshkin, V. S. ^{[7
]}

Desai, A. ^{[8
]}

Feng, S. ^{[2
]}

Angelidakis, A. ^{[2
]}

Johnson, M. S. ^{[9
]}

Fong, L. ^{[10
]}

Hope, T. ^{[11
]}

机构：

[1] Univ Calif San Francisco, Med Dept, Parnassus Campus, San Francisco, CA USA

[2] UCSF Univ Calif San Francisco, Canc Ctr, San Francisco, CA USA

[3] UCSF Univ Calif San Francisco, Med, San Francisco, CA USA

[4] UCSF Helen Diller Family Comprehens Canc Ctr, Comprehens Canc Ctr, San Francisco, CA USA

[5] UCSF Univ Calif San Francisco, Radiat Oncol, Parnassus Campus, San Francisco, CA USA

[6] UCSF Univ Calif San Francisco, Anat, San Francisco, CA USA

[7] UCSF Helen Diller Family Comprehens Canc Ctr, Div Med Oncol, San Francisco, CA USA

[8] Univ Calif San Francisco, Dept Med, San Francisco, CA USA

[9] UCSF Med Ctr Mission Bay, Genitourinary Oncol Dept, San Francisco, CA USA

[10] UCSF Diabet Teaching Ctr, Med Dept, San Francisco, CA USA

[11] UCSF Univ Calif San Francisco, Radiol, San Francisco, CA USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1379P

引用

页码：S1173 / S1173

页数：1

共 50 条

[1] PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
Sandhu, S. K.
Joshua, A. M.
Emmett, L.
Spain, L.
Horvath, L. G.
Crumbaker, M.
Anton, A.
Wallace, R.
Pasam, A.
Bressel, M.
Cassidy, E.
Banks, P.
Kumar, A. R.
Alipour, R.
Akhurst, T.
Kong, G.
Davis, I. D.
Williams, S.
Hicks, R.
Hofman, M.
ANNALS OF ONCOLOGY, 2021, 32 : S626 - S627
[2] Immunogenic priming with 177Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study.
Aggarwal, Rahul Raj
Sam, Srey Luch
Koshkin, Vadim S.
Small, Eric Jay
Feng, Felix Y.
de Kouchkovsky, Ivan
Kwon, Daniel H.
Friedlander, Terence W.
Borno, Hala
Bose, Rohit
Chou, Jonathan
Desai, Arpita
Rodvelt, Tammy J.
Aslam, Maya
Rastogi, Medini
Fong, Lawrence
Hope, Thomas A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
Tagawa, S. T.
Vallabhajosula, S.
Jhanwar, Y.
Hackett, A.
Oromendia, C.
Naiz, M. J.
Goldsmith, S. J.
Nanus, D. M.
Beltran, H.
Molina, A. M.
Faltas, B.
Sreekumar, J.
Babich, J.
Ballman, K.
Bander, N. H.
ANNALS OF ONCOLOGY, 2018, 29
[4] PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
Sandhu, Shahneen
Joshua, Anthony M.
Emmett, Louise
Spain, Lavinia Anne
Horvath, Lisa
Crumbaker, Megan
Anton, Angelyn
Wallace, Roslyn
Pasam, Anupama
Bressel, Mathias
Cassidy, Erin
Banks, Patricia
Dhiantravan, Nattakorn
Akhurst, Timothy J.
Kumar, Aravind Ravi
Alipour, Ramin
Scalzo, Mark
Williams, Scott
Hicks, Rodney
Hofman, Michael S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] Phase I dose-escalation study of fractionated-dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
Tagawa, Scott T.
Vallabhajosula, Shankar
Batra, Jaspreet
Christos, Paulj.
Jhanwar, Yuliya
Goldsmith, Stanley J.
Nanus, David M.
Beltran, Himisha
Molina, Ana M.
Faltas, Bishoy
Hackett, Amy
Sreekumar, Jyothi
Babich, John
Bander, Neil Harrison
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[6] LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)
Sandhu, Shahneen
Joshua, Anthony M.
Emmett, Louise
Crumbaker, Megan
Bressel, Mathias
Huynh, Rhonda
Banks, Patricia Diana
Wallace, Roslyn
Hamid, Anis
Inderjeeth, Andrisha Jade
Tran, Ben
Azad, Arun
Alipour, Ramin
Kong, Grace
Kumar, Aravind Ravi
Saghebi, Javad
Williams, Scott
Akhurst, Timothy J.
Hicks, Rodney J.
Hofman, Michael S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[7] Final results of phase I/II trial of fractionated dose 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC)
Tagawa, S. T.
Sun, M.
Sartor, O.
Thomas, C.
Molina, A. M.
Sternberg, C. N.
Nanus, D. M.
Osborne, J.
Bander, N.
ANNALS OF ONCOLOGY, 2021, 32 : S645 - S645
[8] A long-term outcome study on 177Lu-PSMA617 Radioligand Therapy in metastatic castration Resistant Prostate Cancer: "Single-institutional Results
Yadav, Madhav
Ballal, Sanjana
Sahoo, Ranjit
Tripathi, Madhavi
Damle, Nishikant
JOURNAL OF NUCLEAR MEDICINE, 2019, 60
[9] Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
Tagawa, S. T.
Osborne, J. R.
Hackett, A.
Niaz, M. J.
Cooley, V.
Christos, P.
Vlachostergios, P. J.
Thomas, C.
Gracey, L.
Beltran, H.
Molina, A. M.
Nanus, D. M.
Babich, J.
Vallabhajosula, S.
Sartor, O.
Ballman, K.
Bander, N. H.
ANNALS OF ONCOLOGY, 2019, 30
[10] Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
Tagawa, Scott T.
Thomas, Charlene
Nauseef, Jones T.
Sartor, A. Oliver
Sun, Michael Philip
Castellanos, Sandra Huicochea
Fajardo, Andres Ricaurte
Beltran, Himisha
Demichelis, Francesca
Sigouros, Michael
Orlando, Francesco
Molina, Ana M.
Davidson, Zachary
Patel, Amie
Lewis, Brian E.
Nanus, David M.
Vallabhajosula, Shankar
Bander, Neil Harrison
Osborne, Joseph
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →